Combination chemotherapy of abraxane and carboplatin in elderly patients with advanced squamous cell lung cancer, phase 1/2 study (TORG1322)
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Primary endpoint (6-month progression-free survival ) has been met according to Results presented at the 20th World Conference on Lung Cancer.
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.